Yankcom Partnership Viking Therapeutics, Inc. Transaction History
Yankcom Partnership
- $182 Billion
- Q1 2025
A detailed history of Yankcom Partnership transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Yankcom Partnership holds 1,133 shares of VKTX stock, worth $32,992. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,133
Previous 821
38.0%
Holding current value
$32,992
Previous $33 Million
17.19%
% of portfolio
0.02%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding VKTX
# of Institutions
436Shares Held
65.3MCall Options Held
8.28MPut Options Held
3.39M-
Vanguard Group Inc Valley Forge, PA10.2MShares$296 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$175 Million0.01% of portfolio
-
State Street Corp Boston, MA4.06MShares$118 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY3.13MShares$91 Million0.01% of portfolio
-
Morgan Stanley New York, NY3.12MShares$90.9 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.23B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...